With your own knowledge and the help of the following document:

Document 1 (Title: Epidemiology of Atherosclerotic Cardiovascular Disease): Coronary artery disease continues to represent a leading cause of morbidity and mortality worldwide, with extensive epidemiological research identifying multiple modifiable and non-modifiable risk factors contributing to its development. Tobacco exposure, particularly cigarette smoking, consistently demonstrates among the strongest modifiable risk associations, with large cohort studies documenting 2-4 fold increased relative risk in current smokers compared to never-smokers, alongside dose-dependent relationships with cumulative exposure. Lipoprotein abnormalities play central roles in atherogenesis, with elevated apolipoprotein B concentrations representing a particularly strong predictor of coronary risk regardless of corresponding LDL-cholesterol levels. This relationship reflects apolipoprotein B's presence on all atherogenic lipoprotein particles, providing superior risk prediction compared to traditional lipid measurements in multiple prospective studies. Elevated blood pressure constitutes another firmly established risk factor, with each 20 mmHg systolic or 10 mmHg diastolic increase associated with approximately doubling of cardiovascular mortality across the entire blood pressure range starting from 115/75 mmHg. More recently, lipoprotein(a) has emerged as an independent risk factor, with elevated plasma levels conferring significantly increased coronary risk through both atherogenic and prothrombotic mechanisms resistant to conventional lipid-lowering approaches. Protective factors have also been identified, with high-density lipoprotein (HDL) demonstrating inverse association with coronary risk, reflecting its crucial role in reverse cholesterol transport and various anti-inflammatory functions. However, recent intervention trials targeting HDL have emphasized that its relationship with coronary disease appears more complex than initially conceptualized, with functional characteristics potentially more important than absolute concentration measurements. These collective findings inform current risk assessment algorithms and targeted intervention strategies for primary and secondary coronary disease prevention.
Document 2 (Title: Genetic Determinants of Lipoprotein Metabolism and Vascular Disease): High-density lipoprotein cholesterol (HDL-C) represents a complex, heterogeneous lipoprotein fraction historically associated with cardioprotective effects, though the causal nature of this relationship has been increasingly questioned. While epidemiological studies consistently demonstrate inverse associations between HDL-C levels and cardiovascular disease (CVD) risk, genetic studies and therapeutic trials targeting HDL-C have yielded inconsistent results, suggesting more complex relationships than initially proposed. Mutations causing low HDL-C occur through various mechanisms, predominantly affecting apolipoprotein A-I (the principal HDL protein component), ATP-binding cassette transporter A1 (ABCA1, mediating cellular cholesterol efflux), lecithin-cholesterol acyltransferase (LCAT, catalyzing cholesterol esterification), or cholesteryl ester transfer protein (CETP, facilitating lipid exchange between lipoproteins). These genetic variants produce distinct HDL particle compositions beyond simply reduced cholesterol content, potentially explaining divergent clinical manifestations. Surprisingly, detailed phenotypic characterization of subjects with genetically determined low HDL-C has not consistently demonstrated the accelerated atherosclerosis predicted by epidemiological associations. Particularly compelling evidence comes from studies of ABCA1 mutation carriers (Tangier disease), who despite profoundly reduced HDL-C levels, demonstrate only modestly increased cardiovascular risk. Similarly, LCAT deficiency, while producing dramatic HDL reduction, shows inconsistent associations with premature atherosclerosis. Even apoA-I mutations, affecting the structural protein of HDL, demonstrate variable vascular phenotypes not consistently correlating with HDL-C reduction magnitude. Contemporary mechanistic research suggests HDL functionality—its capacity to promote reverse cholesterol transport, exert anti-inflammatory effects, and maintain endothelial function—may be more relevant to cardiovascular protection than absolute HDL-C concentration. This functionality appears partially independent of HDL-C levels, explaining apparent discrepancies between epidemiological associations and genetic studies. Subclinical atherosclerosis assessment through carotid intima-media thickness (cIMT) measurement has been particularly informative, with multiple studies specifically examining the relationship between genetically determined low HDL-C and vascular structure. These investigations consistently demonstrate that isolated genetic causes of low HDL-C without accompanying metabolic perturbations do not significantly increase cIMT compared to controls, contradicting predictions based solely on HDL-C levels. This dissociation between HDL-C concentration and vascular phenotype has profound implications for therapeutic approaches targeting HDL, suggesting intervention efficacy may depend on functional improvements rather than simple quantitative HDL-C elevation.
Document 3 (Title: Nitroglycerin): Nitroglycerin is a vasodilatory drug used primarily to provide relief from anginal chest pain. Nitroglycerin has been FDA approved since 2000 and was first sold as a brand name agent. It is currently FDA approved for the acute relief of an attack or acute prophylaxis of angina pectoris secondary to coronary artery disease. Off label, non FDA approved uses include treatment for hypertensive urgency/emergency, coronary artery spasm, angina secondary to cocaine use, congestive heart failure (CHF), and chronic anal fissures. Along with hydralazine as a combination therapy, it is also indicated in patients with heart failure with reduced ejection in whom ACE inhibitors are contraindicated. Nitroglycerin is occasionally given to reduce radial spasms during coronary angiography through the radial approach. Nitroglycerin was first used in 1879 as a treatment for angina and since it has been part of management to relieve anginal chest pain.[1] Although nitroglycerin has a vasodilatory effect in both arteries and veins, the profound desired effects caused by nitroglycerin are primarily due to venodilation.[2] Venodilation causes pooling of blood within the venous system, reducing preload to the heart, which causes a decrease in cardiac work, reducing anginal symptoms secondary to demand ischemia. Arterial vasodilation will still occur and contribute to the relief of anginal symptoms.[3][4] Vasodilation of the coronary arteries will cause increased blood flow to the heart, increasing perfusion, but this effect remains minimal compared to the effects of venodilation.

Answer the following list question.
Question: Select the risk factor(s) for coronary artery disease:
Options:
1. Smoking
2. High plasma concentration of apolipoprotein B
3. High plasma concentration of HDL
4. Hypertension
5. High plasma level of Lp(a)

Respond strictly in valid JSON format as shown below:
{"answer": ["1", "3"]} ← if options 1 and 3 are correct
Only output the JSON object. Do not include explanations, labels, markdown, or any other text.